Co-Diagnostics Posts $1.01 Per-Share Q3 Loss as Cash Crunch Deepens
CODX sits 49% above its 52-week low of $0.245 on elevated volume (32× avg).
Summary
Co-Diagnostics reported a third-quarter loss of $1.01 per share on revenue of $282,881, with a net loss of $6.31M and operating expenses down 12%. The per-share loss dwarfs the $0.3652 share price and follows a Q2 loss of $1.46 per share. The company is burning cash with a going concern warning already on the books — Q2 cash stood at $3.6M against a $15.4M six-month net loss. Financing has turned punitive: an October 8-K disclosed a $2.1M convertible loan with a 35% original issue discount and all ATM proceeds pledged to the lender, and a November 4 S-3 registered 39,594,495 resale shares for that lender. A court-ordered special meeting on November 13 will ask holders to approve a reverse split of up to 1-for-50 and warrant exercises. Watch the November 13 vote — failure to pass the reverse split and warrant proposals leaves the company without its main near-term liquidity lever.
At the time of this announcement, CODX was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.25 to $13.54. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.